Home›Companies›Biotech & Pharma›ILiAD

Iliad Biotechnologies, Inc.

Develops an investigational whooping cough vaccine for people at risk of infection.

Updated Nov 11, 2026·Latest SEC filing Feb 20, 2026·Suggest an edit

About ILiAD

ILiAD is a private company based in Weston, Florida, incorporated in 2026 in Delaware. It has reported $115,540,057 raised in one offering on Form D since February 2026.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Feb 5, 2026Feb 20, 2026$115,540,057fully sold36$3.2MEquityRule 506(b)Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on ILiAD's Form D filed Feb 20, 2026.

WS
William Steinkrauss
Executive officer
Also an executive officer at OcuTerra Therapeutics.
Avi Naider
Avi Naider
Board Member
Also a director at Treeline Biosciences.
Mario Barro
Mario Barro
Board Member
Eric Edidin
Eric Edidin
Board Member
Keith Rubin
Keith Rubin
Board Member

Sources

  1. SECILIAD BIOTECHNOLOGIES, INC. filing history
  2. CompanyPrivacy notice
  3. CompanyCompany overview
  4. CompanyExecutive board